BIOC - Biocept, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Biocept, Inc.

5810 Nancy Ridge Drive
San Diego, CA 92121
United States

IndustryMedical Laboratories & Research
Full Time Employees80

Key Executives

Mr. David F. HaleExec. ChairmanN/AN/A68
Mr. Michael W. NallCEO, Pres & Director526.25kN/A54
Dr. Lyle J. Arnold Ph.D.Chief Scientific Officer, Sr. VP - R&D and Member of Scientific Advisory Board340.32kN/A70
Dr. Veena M. Singh M.D.SVP, Sr. Medical Director & Member of Scientific Advisory Board361.03kN/A42
Dr. Soon Kap Hahn Ph.D.FounderN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company’s cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Corporate Governance

Biocept, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.